Evidence map›Paper›PMID 26497143›Full record

ArticleG3 (Bethesda, Md.)2015

SMRT Sequencing for Parallel Analysis of Multiple Targets and Accurate SNP Phasing.

Xiaoge Guo, Kevin Lehner, Karen O'Connell, Jenny Zhang, Sandeep S Dave, Sue Jinks-Robertson

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Mitotic recombination in yeast: what we know and what we don't know.Current opinion in genetics & development · 2021
    Review
  4. Article
  5. Polymorphic tandem DNA repeats activate the human telomerase reverse transcriptase gene.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoge GuoGraduate Program in Molecular Cancer Biology, Duke University, Durham, North Carolina 27710.
Kevin LehnerUniversity Program in Genetics and Genomics, Duke University, Durham, North Carolina 27710.
Karen O'ConnellUniversity Program in Genetics and Genomics, Duke University, Durham, North Carolina 27710.
Jenny ZhangUniversity Program in Genetics and Genomics, Duke University, Durham, North Carolina 27710.
Sandeep S DaveDuke Cancer Institute, Duke University, Durham, North Carolina 27710 Department of Medicine, Duke University, Durham, North Carolina 27710.
Sue Jinks-RobertsonDuke Cancer Institute, Duke University, Durham, North Carolina 27710 Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina 27710 sue.robertson@duke.edu.

Funding

Genetics Training Grant-Year 26T32GM007754 · NIGMS · DUKE UNIVERSITY · PI HAASE, STEVEN B · 1985 to 2019
$8.3M
REGULATION OF MITOTIC RECOMBINATION IN YEASTR01GM038464 · NIGMS · EMORY UNIVERSITY · PI JINKS-ROBERTSON, SUE · 1992 to 2015
$3.6M
Understanding the context-dependent roles of mutations in lymphoma.R01CA136895 · NCI · DUKE UNIVERSITY · PI DAVE, SANDEEP · 2009 to 2018
$2.7M
Topoisomerase 1 and mutagenesis in yeastR01GM101690 · NIGMS · DUKE UNIVERSITY · PI JINKS-ROBERTSON, SUE · 2012 to 2015
$1.3M
Transcription-associated mutagenesis in yeastR01GM093197 · NIGMS · DUKE UNIVERSITY · PI JINKS-ROBERTSON, SUE · 2010 to 2013
$1.2M
RECOMBINATION BETWEEN REPEATED SEQUENCE IN YEASTR29GM038464 · NIGMS · EMORY UNIVERSITY · PI JINKS-ROBERTSON, SUE · 1987 to 1991
–
NCI NIH HHS CA136895NCI NIH HHS R01 CA136895NIGMS NIH HHS GM038464NIGMS NIH HHS GM093197NIGMS NIH HHS GM101690NIGMS NIH HHS R01 GM038464NIGMS NIH HHS R01 GM093197NIGMS NIH HHS R01 GM101690NIGMS NIH HHS T32 GM007754
6 · The paper itself

Abstract

Single-molecule real-time (SMRT) sequencing generates much longer reads than other widely used next-generation (next-gen) sequencing methods, but its application to whole genome/exome analysis has been limited. Here, we describe the use of SMRT sequencing coupled with barcoding to simultaneously analyze one or a small number of genomic targets derived from multiple sources. In the budding yeast system, SMRT sequencing was used to analyze strand-exchange intermediates generated during mitotic recombination and to analyze genetic changes in a forward mutation assay. The general barcoding-SMRT approach was then extended to diffuse large B-cell lymphoma primary tumors and cell lines, where detected changes agreed with prior Illumina exome sequencing. A distinct advantage afforded by SMRT sequencing over other next-gen methods is that it immediately provides the linkage relationships between SNPs in the target segment sequenced. The strength of our approach for mutation/recombination studies (as well as linkage identification) derives from its inherent computational simplicity coupled with a lack of reliance on sophisticated statistical analyses.

Indexed as

Polymorphism, Single NucleotideAllelesCell Line, TumorDNA Barcoding, TaxonomicDNA Mutational AnalysisGenes, FungalGenetic LinkageGenomicsHigh-Throughput Nucleotide SequencingHumansLymphomaMutationRecombination, GeneticReproducibility of ResultsYeastsbarcoded sequencingPacBiorare variantsingle-molecule sequencingSNP linkage

Identifiers

PMID26497143
PMCPMC4683651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.